- Editor's PickYahoo Finance•57 minutes ago
Pfizer (PFE) shares remain in the spotlight. The US drug maker that bought cancer drug firm Medivation (MDVN) just a couple of days ago is now buying part of AstraZeneca’s (AZN) antibiotics business. FitBit (FIT) shares got a healthy pop ahead of the open after a US trade judge ruled late Tuesday that the maker of wearable fitness trackers did not steal trade secrets from rival Jawbone.
- Editor's PickSeana Smith•2 days ago
Pfizer is buying Medivation for $14 billion. Medivation’s portfolio includes Xtandi, a treatment for prostate cancer that generates about $2 billion in worldwide annual sales. Valeant Pharmaceuticals (VRX) — Zoetis (ZTS) Chief Financial Officer Paul Herendeen has stepped down to become executive vice president of finance at Valeant and will take over the role of CFO from Robert Rosiello effective immediately.
- Editor's PickJulia La Roche•2 days ago
On Monday, Medivation’s (MDVN) stock surged around 20% after pharma giant Pfizer (PFE) said it would acquire the biotech company in a $14 billion deal. Medivation just made its debut on Goldman Sachs’ 50 stocks that “matter most” to hedge funds list, ranking No. 17 on the list. Some hedge funds that opened a new position in Medivation during the second quarter include York Capital Management (5.07 million shares), Tourbillon Capital Partners (4.72 million shares), Pentwater Capital (4.28 million shares), and Eton Park Capital Management (3.08 million shares), 13-F filings show.
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||35.35 x 5600|
|Ask||35.36 x 2800|
|Day's Range||35.09 - 35.38|
|52wk Range||28.25 - 37.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||31.25|
|Avg Vol (3m)||22,247,406|
|Dividend & Yield||1.20 (3.44%)|